BindingDB logo
myBDB logout

53 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27876250 60 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI Jagiellonian University Medical College
27480029 6 Exploring new scaffolds for angiotensin II receptor antagonism.EBI National Hellenic Research Foundation
26824643 69 Mimicking of Arginine by Functionalized N(┐)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.EBI University of Regensburg
26988801 55 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI Jagiellonian University Medical College
25699147 6 Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.EBI Uppsala University
25313325 8 Saralasin and Sarile Are AT2 Receptor Agonists.EBI Universit£ de Sherbrooke
25254961 32 Optimized protein kinase C┐ (PKC┐) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis.EBI AbbVie Bioresearch Center
24625069 28 Structure-activity relationship studies toward the discovery of selective apelin receptor agonists.EBI UMR7200 CNRS/Universit£ de Strasbourg
23265881 49 Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.EBI Pfizer Inc.
19757839 26 The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues.EBI Vrije Universiteit Brussel
21413808 170 Synopsis of some recent tactical application of bioisosteres in drug design.EBI Bristol-Myers Squibb Pharmaceutical Research and Development
22931505 69 Chemokine receptor antagonists.EBI National Heart and Lung Institute
23010269 145 Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor.EBI Sanford-Burnham Medical Research Institute
22889560 16 The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.EBI University of Patras
22727371 22 Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT1 receptor antagonists.EBI School of Chemical Engineering& the Environment
22750010 30 Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.EBI China Pharmaceutical University
20875743 90 Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relaEBI Pfizer Inc.
20493713 30 Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.EBI Uppsala University
16220969 219 Designed multiple ligands. An emerging drug discovery paradigm.EBI Organon Laboratories
12773029 8 Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.EBI Technische Universit£t Darmstadt
8576904 78 Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.EBI DuPont Merck Pharmaceutical Company
8709104 10 Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.EBI Washington University
22309912 28 Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.EBI Beijing Institute of Technology
21683484 8 Application of Ullmann and Ullmann-Finkelstein reactions for the synthesis of N-aryl-N-(1H-pyrazol-3-yl) acetamide or N-(1-aryl-1H-pyrazol-3-yl) acetamide derivatives and pharmacological evaluation.EBI INSERM
21557540 39 Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.EBI Pfizer Inc.
21071232 78 Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.EBI The M. S. University of Baroda
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
20146480 8 The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1.EBI Universite de Sherbrooke
20079636 78 Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.EBI Centre de Recherches
 60 The SAR of 6-(N-alkyl-N-acyl)-2-propyl-3-[(2′-tetrazol-5-yl)biphen-4-yl)methyl]-quinazolinones as balanced affinity antagonists of the human AT1 and AT2 receptorsEBI TBA
 3 D and L-N-[(1-benzyl-1H-imidazol-5-yl)-alkyl]-amino acids as angiotensin II AT-1 antagonistsEBI TBA
 56 Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT1 and AT2 subtypesEBI TBA
 134 Development of angiotensin II antagonists with equipotent affinity for human AT1 and AT2 receptor subtypes.EBI TBA
 122 Balanced angiotensin II receptor antagonists. III. The effects of substitution at the imidazole 5-position.EBI TBA
 68 Balanced angiotensin II receptor antagonists. II.1,2 4-aminomethyl- and acylaminomethylimidazolesEBI TBA
 19 Imidazolinones as nonpeptide angiotensin II receptor antagonistsEBI TBA
 11 Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid seriesEBI TBA
 12 A potent long-acting imidazole-5-acrylic acid angiotensin II AT-1 receptor antagonistEBI TBA
14761190 10 Recognition of privileged structures by G-protein coupled receptors.EBI Novo Nordisk A/S
12361407 4 Comparison of 3D structures and AT(1) binding properties of pyrazolidine-3,5-diones and tetrahydropyridazine-3,6-diones with parent antihypertensive drug irbesartan.EBI Université de Lille 2
12190306 14 Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12113820 4 Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects.EBI Wyeth Research
10893306 21 Synthesis and pharmacological evaluation of new pyrazolidine-3, 5-diones as AT(1) angiotensin II receptor antagonists.EBI Université de Lille 2
7629811 19 Novel angiotensin II receptor antagonists. Design, synthesis, and in vitro evaluation of dibenzo[a,d]cycloheptene and dibenzo[b,f]oxepin derivatives. Searching for bioisosteres of biphenylyltetrazole using a three-dimensional search technique.EBI Shionogi & Co., Ltd.
7562905 258 Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.EBI Merck Research Laboratories
15131245 86 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
12570021 16 Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors.BDB Shinshu University
9454810 72 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB Sanofi Recherche